Revance Therapeutics Faces Class Action Lawsuit: Investors May Lead the Charge

LOS ANGELES, Jan. 23, 2025 /PRNewswire/ — Glancy Prongay & Murray LLP has announced that investors who suffered losses have the chance to take the lead in a securities fraud class action against Revance Therapeutics, Inc. (“Revance” or the “Company”) RVNC.

IF YOU EXPERIENCED A LOSS ON YOUR REVANCE INVESTMENTS, CLICK HERE BEFORE MARCH 4, 2025 (LEAD PLAINTIFF DEADLINE) TO JOIN THE SECURITIES FRAUD LAWSUIT

Details of the Lawsuit:
The complaint states that between February 29, 2024 and December 6, 2024, the Defendants failed to inform investors that: (1) Revance was in serious breach of the Distribution Agreement; (2) this breach exposed the Company to higher risks of lawsuits and caused potential financial and reputational damage; (3) these issues raised the likelihood that the Tender Offer might be delayed or changed; and (4) therefore, the positive statements made by Defendants regarding the Company’s operations and future were misleading and lacked a solid basis at all times.

Get Involved or Learn More:
If you wish to learn more about this case or have any questions regarding this announcement or your rights, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you contact us by email, please provide your mailing address, phone number, and the number of shares purchased. 

To be part of the class action, you do not need to take any immediate action; you can choose your own lawyer or opt not to take any action and remain part of the class action as an absent member.

This press release may be viewed as Attorney Advertising in some jurisdictions according to applicable law and ethical standards.

Contact Information:
Glancy Prongay & Murray LLP,  
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

View original content to download multimedia: https://www.prnewswire.com/news-releases/revance-therapeutics-inc-rvnc-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302358265.html

SOURCE Glancy Prongay & Murray LLP